Press Releases View all 10 hits
Press Releases • May 09, 2014 09:38 GMT
A presentation on the importance of global viral load monitoring to contain the HIV pandemic.
Press Releases • Apr 11, 2014 06:00 GMT
Press Releases • Nov 15, 2013 09:29 GMT
Leading Swedish HIV diagnostic company Cavidi today announced the signing of a license agreement for technology in the detection of CD4 T-cell levels. The CD4 test, developed by the Burnet Institute in Melbourne, Australia, and a long time partner to Cavidi, can be added to Cavidi’s Viral Load test on the next generation automated bench top instrument.
News View all 18 hits
News • Jul 03, 2014 09:36 GMT
News • May 12, 2014 10:10 GMT
News • Apr 30, 2013 13:37 GMT
Blog posts 4 hits
Blog posts • Nov 28, 2013 09:50 GMT
Each year World Aids Day helps raise awareness around the world. It’s also a time for everyone involved in the fight against HIV to step back and assess our progress. Looking at the HIV community as a whole and Cavidi in particular, I can say it’s been a good year overall. We have seen great progress in the treatment of HIV worldwide.
Blog posts • Jul 23, 2012 10:30 GMT
There are around 370,000 new infant infections worldwide each year. A significant number of these children will die if they are not diagnosed early and started on antiretroviral drugs (ARVs). The problem is not the lack of ARVs as much as a lack of proper HIV early infant diagnostics (EID). Recent reports indicate that RT-technology may be an answer to improved access to (EID).
Blog posts • Oct 13, 2011 08:52 GMT
Although the North American and Western European experience has historically been with HIV-1 group M subtype B virus, this is changing rapidly as migrants and refugees from developing countries with non-B subtype infections now present for care in the developed world, and travelers to developing countries acquire non-B subtype infection abroad and present for care at home.
Images 4 hits
Videos 2 hits
Documents 3 hits
Documents • Sep 09, 2013 10:48 GMT
Routine use of viral load testing makes business sense: it will save money on drugs with effective monitoring of patients. MSF identifies the needs of a solution in a wish list on p23. This is the market opportunity that Cavidi is seeking to address with our new platform (Q42014) meeting requirements that MSF have identified for laboratory-based tests. Cavidi ref on p 5,20,21,23,30,and 31.